Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia.

ABSTRACT:

Background

The safety and efficacy of vaccines to prevent Ebola virus disease (EVD) were unknown when the incidence of EVD was peaking in Liberia.

Methods

We initiated a randomized, placebo-controlled, phase 3 trial of the chimpanzee adenovirus 3 vaccine (ChAd3-EBO-Z) and the recombinant vesicular stomatitis virus vaccine (rVSV∆G-ZEBOV-GP) in Liberia. A phase 2 subtrial was embedded to evaluate safety and immunogenicity. Because the incidence of EVD declined in Liberia, the phase 2 component was expanded and the phase 3 component was eliminated.

Results

A total of 1500 adults underwent randomization and were followed for 12 months. The median age of the participants was 30 years; 36.6% of the participants were women. During the week after the administration of vaccine

SUBMITTER: Kennedy SB 

PROVIDER: S-EPMC5705229 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature